MPS (MyProstateScore)

Test Overview

Test Methodology

Transcription Mediated Amplification (TMA) and Hybrid Protection Assay (HPA)

Test Usage

Adjunct to serum prostate specific antigen (PSA) for risk stratification of patients undergoing prostate biopsy. MPS incorporates serum PSA, urine PCA3 score, and urine TMPRSS2: ERG score in logistic regression models to derive scores giving the risk of detecting high grade (Gleason score >7) prostate cancer on diagnostic needle biopsy.

Reference Range*

The TMPRSS2: ERG score ranges from 0 to 100, with higher scores associated with an increased risk of high grade cancer on diagnostic biopsy. The MyProstateScore (MPS) report provides a high grade prostate cancer risk score, indicating the risk of high grade prostate cancer (Gleason score >7) on diagnostic needle biopsy.

* Reference ranges may change over time. Please refer to the original patient report when evaluating results.

Test Details

Analytic Time

10 - 14 days

Soft Order Code

MIPS

MiChart Code

MiPS - Mi Prostate Score

Synonyms

MIPS
TMPRSS2:ERG
T2ERG
T2:ERG
PCA3
Prostate Cancer Risk Assesment

+ See More

Laboratory

MCTP Molecular Testing Lab

Looking to Order a Test?

We’ve provided helpful links to make ordering easy.

Find a Requisition

All specimens should be accompanied by a requisition.

Submitting Specimens

Learn about how to properly label and where to ship specimens.

Order Kits and Supplies

MLabs provides all the supplies necessary for the collection of specimens.

Test FAQ

Visit our provider FAQ and learn about common questions to ordering tests.

Specimen Requirements

Special Handing

Attentive DRE must be performed immediately prior to specimen collection. Specimen must be processed within 4 hours of collection. Please refer to Collection Instructions for additional details.

Container

Normal Volume

30 mL urine

Minimum Volume

5 mL urine

Additional Information

A signed Advance Beneficiary Notice of Noncoverage (ABN) form - available at http://mlabs.umich.edu/files/pdfs/ABNEnglish2020v508-MLABS-PCA3.pdf - must accompany any samples sent for PCA3 or MPS testing from Medicare patients when MLabs will be billing Medicare or the patient. By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes pathologist interpretation of results billed as a separate additional charge. This test is not available without interpretation. Ordering clinician must provide serum PSA level (ng/mL) for a MPS report to be generated.